This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ESMO 2021
Presentations
Brentuximab Vedotin | NSCLC or Cutaneous Melanoma | Abstract #3027
A Phase 2 Trial of Pembrolizumab and Brentuximab Vedotin in Patients With Metastatic Solid Malignancies After Progression on Prior Programmed Cell Death Protein-1 Inhibitors (SGN35-033, Trial in Progress)